{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:36:29Z","timestamp":1792708589806,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.coi.2025.102602","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T14:08:18Z","timestamp":1751897298000},"page":"102602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease"],"prefix":"10.1016","volume":"95","author":[{"given":"Disha","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7594-6528","authenticated-orcid":false,"given":"Siba P","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2025.102602_sbref1","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jaut.2016.10.009","article-title":"Management of psoriatic arthritis: early diagnosis, monitoring of disease severity and cutting edge therapies","volume":"76","author":"Raychaudhuri","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102602_bib2","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/14740338.2020.1722640","article-title":"Safety considerations with combination therapies for psoriasis","volume":"19","author":"Nakamura","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.coi.2025.102602_bib3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/1346-8138.12102","volume":"40","author":"Takahashi","year":"2013","journal-title":"J Dermatol"},{"key":"10.1016\/j.coi.2025.102602_bib4","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/jdv.14583","article-title":"Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries","volume":"32","author":"Busard","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.coi.2025.102602_bib5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ng.311","article-title":"Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways","volume":"41","author":"Nair","year":"2009","journal-title":"Nat Genet"},{"key":"10.1016\/j.coi.2025.102602_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01764","article-title":"Adaptive and innate immunity in psoriasis and other inflammatory disorders","volume":"10","author":"Sch\u00f6n","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102602_sbref7","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.jid.5701213","article-title":"Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells","volume":"128","author":"Lowes","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.coi.2025.102602_bib8","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.coi.2025.102602_bib9","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1002\/art.30278","article-title":"Interleukin-17-induced proliferation of fibroblast-like synovial cells is mTOR dependent","volume":"63","author":"Saxena","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.coi.2025.102602_bib10","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1002\/art.39964","article-title":"Functional significance of IL-9 and its receptor system in the pathogenesis of psoriatic arthritis","volume":"69","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102602_bib11","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.41882","article-title":"Targeting the CCR6\/CCL20 axis in entheseal and cutaneous inflammation","volume":"73","author":"Shi","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102602_sbref12","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-216658","article-title":"Polyfunctional TEM cells in psoriatic arthritis synovium skewed towards Th17 cells","volume":"81","author":"Raychaudhuri","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.coi.2025.102602_sbref13","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/PL00000629","article-title":"Anti-interleukin-1 and anti-tumor necrosis factor-alpha synergistically inhibit adjuvant arthritis in Lewis rats","volume":"57","author":"Feige","year":"2000","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.coi.2025.102602_bib14","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1080\/17425255.2019.1681969","article-title":"Pharmacodynamics OF TNF \u03b1 inhibitors for the treatment of psoriasis","volume":"15","author":"Campanati","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.coi.2025.102602_bib15","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1007\/s10067-018-4238-4","article-title":"Clinical outcomes and feasibility of the multidisciplinary management of patients with psoriatic arthritis: two-year clinical experience of a dermo-rheumatologic clinic","volume":"37","author":"Luchetti","year":"2018","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.coi.2025.102602_bib16","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"J Dig Dis"},{"key":"10.1016\/j.coi.2025.102602_sbref17","doi-asserted-by":"crossref","DOI":"10.1177\/17562848211006669","article-title":"Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches","volume":"14","author":"Privitera","year":"2021","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.coi.2025.102602_sbref18","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1283251","article-title":"Dual targeted therapy in patients with psoriatic arthritis and spondyloarthritis: a real-world multicenter experience from Spain","volume":"14","author":"Valero-Mart\u00ednez","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2025.102602_bib19","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3899\/jrheum.110295","article-title":"Combination biologic treatment of refractory psoriasis and psoriatic arthritis","volume":"39","author":"Cuchacovich","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.coi.2025.102602_bib20","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jdcr.2014.09.002","article-title":"Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: a case report","volume":"1","author":"Babalola","year":"2014","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.coi.2025.102602_bib21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/bjd.14270","article-title":"Combination of antitumour necrosis factor-\u03b1 and anti-interleukin-12\/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study","volume":"174","author":"Gniadecki","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.coi.2025.102602_bib22","first-page":"394","article-title":"Successful treatment of refractory plaque-type psoriasis and psoriatic arthritis with guselkumab and adalimumab combination therapy: a case report","volume":"18","author":"Rathod","year":"2019","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coi.2025.102602_bib23","first-page":"1098","article-title":"Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center","volume":"12","author":"Heinecke","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.coi.2025.102602_sbref24","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","article-title":"Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate","volume":"70","author":"Mease","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.coi.2025.102602_bib25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1093\/rheumatology\/key312","article-title":"Exposure-response analyses demonstrate no evidence of interleukin 17A contribution to efficacy of ABT-122 in rheumatoid or psoriatic arthritis","volume":"58","author":"Khatri","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.coi.2025.102602_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2025.102602_bib27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2025.102602_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/ijd.ijd_569_22","article-title":"Recent update on immunopathogenesis of psoriasis","volume":"67","author":"Chhabra","year":"2022","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coi.2025.102602_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jaut.2014.07.003","article-title":"Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCIDmouse psoriasis - xenograft model","volume":"55","author":"Kundu-Raychaudhuri","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.coi.2025.102602_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0079-6123(03)46027-5","article-title":"Role of NGF and neurogenic inflammation in the pathogenesis of psoriasis","volume":"146","author":"Raychaudhuri","year":"2004","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.coi.2025.102602_bib31","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4103\/0019-5154.123499","article-title":"mTOR signaling cascade in psoriatic disease: double kinase mTOR inhibitor a novel therapeutic target","volume":"59","author":"Raychaudhuri","year":"2024","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.coi.2025.102602_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","article-title":"Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis","volume":"19","author":"Ovejero-Benito","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.coi.2025.102602_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1039688","article-title":"An innovative framework to determine the implementation level of personalized medicine: a systematic review","volume":"11","author":"Aguilera-Cobos","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.coi.2025.102602_bib34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/PTT.S328460","article-title":"Towards personalized medicine in psoriasis: current progress","volume":"12","author":"Camela","year":"2022","journal-title":"Psoriasis"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000780?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791525000780?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:06:08Z","timestamp":1779084368000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791525000780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":34,"alternative-id":["S0952791525000780"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2025.102602","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concept of dual immune inhibitors for the treatment of drug-resistant psoriatic disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2025.102602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102602"}}